Afya(US:AFYA)2023-03-23 03:07Financial Data and Key Metrics Changes - Adjusted net revenue increased by 32% year-over-year, reaching R$2,319 million, with adjusted EBITDA growth of over 27%, totaling R$962 million and a margin of 41.5% [7][15] - Net income for 2022 reached R$393 million, a growth of 62% year-over-year, with EPS of R$4.14, reflecting a 73% increase compared to the previous year [8][17] - Cash flow generation ended the year at R$877 million, a 32% increase from the previous year, with a cash conversion rate of 94% [7][17] Business Line Data and Key Metrics Changes - The number of operating medical seats increased by over 11% year-over-year, reaching 2,773, with a total of 3,163 medical operating seats after recent acquisitions [8][10] - Continuing Education segment revenue grew by more than 49% year-over-year, reaching R$109 million, driven by the resumption of practical classes and new campus openings [8][20] - Digital Health Services revenue increased by 25% year-over-year, attributed to B2B engagements and new contracts with pharmaceutical companies [9][21] Market Data and Key Metrics Changes - The ecosystem now has 260,000 active users, representing significant penetration among physicians and medical students in Brazil [9][21] - The number of medical students grew by 12% year-over-year, reaching almost 18,000 students [18] Company Strategy and Development Direction - The company aims to maintain 100% occupancy in all medical schools and expects adjusted net revenue for 2023 to be between R$2,750 million and R$2,850 million [13] - The strategy includes expanding the Continuing Education and Digital Services segments, which are expected to grow more rapidly than the Undergrad segment [40] Management's Comments on Operating Environment and Future Outlook - Management highlighted the competitive environment in the prep course market and the expectation of a more consistent recovery in the upcoming cycles [26][27] - There is optimism regarding the new Mais Médicos program, which is expected to incentivize more physicians in underserved regions [28][29] Other Important Information - The company celebrated several awards in 2022, reflecting its commitment to transforming health and education [14] - The net debt remained stable at R$1,381 million, supported by strong cash generation [22] Q&A Session Summary Question: About the prep course revenue decline and outlook - Management acknowledged the competitive landscape affecting Medcel and indicated a slow recovery, expecting better results in the next cycle starting in Q4 2023 [26][27] Question: Guidance on margins and cash generation - Management explained that the guidance includes the impact of new acquisitions and the mix of lower-margin Continuing Education, which may pressure overall margins [31][32] Question: Regulation and future growth in Continuing Education - Management expressed confidence in the growth potential of Continuing Education, aiming to reach 10,000 students by 2026 [38] Question: Impact of new Mais Médicos program on ticket adjustments - Management indicated that the new program may not significantly alter the supply-demand balance but expects to maintain occupancy and adjust tuition accordingly [44][45] Question: Reshaping of Medcel and margin increase - Management confirmed a significant price increase for Medcel and attributed margin expansion to the recovery in Continuing Education and strong B2B performance in Digital Services [49][50]